Advertisement

Parvovirus B19-Infektion

  • T. F. Schwarz

Zusammenfassung

Das humane Parvovirus B19 wurde 1975 zufällig beim Screening von Blutkonserven auf das Oberflächenantigen des Hepatitis B-Virus in Plasmen gesunder Blutspender entdeckt [1]. Aufgrund seiner physikalisch-chemischen Eigenschaften ließ es sich der Familie der Parvoviridae zuordnen. Bis zum Anfang der 80er Jahre allerdings konnte dieses Virus mit keiner klinischen Symptomatik assoziert werden.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Cossart YE, Cant B, Field AM, Widdows D (1975) Parvoviras-like particles in human sera. Lancet ii :72–73CrossRefGoogle Scholar
  2. 2.
    Mori J, Beattie P, Melton DW, Cohen BJ, Clewley JP (1987) Structure and mapping of the DNA of human parvovirus B19. J gen Virol 68:2797–2806PubMedCrossRefGoogle Scholar
  3. 3.
    Ozawa K, Kurtzman G, Young N (1986) Replication of the B19 parvovirus in human bone marrow cell cultures. Science 233:883–886PubMedCrossRefGoogle Scholar
  4. 4.
    Yaegashi N, Shiraishi H, Takeshita T, Nakamura M, Yajima A, Sugamura K (1989) Propagation of human parvovirus B19 in primary culture of erythroid lineage cells derived from fetal liver. J Virol 63:2422–2426PubMedGoogle Scholar
  5. 5.
    Takahashi T, Ozawa K, Mitani K, Miyazono K, Asano S, Takaku F (1989) B19 parvovirus replicates in erythroid leukemic cells in vitro. J Inf Dis 160:548–549CrossRefGoogle Scholar
  6. 6.
    Schwarz TF, Roggendorf M, Deinhardt F (1987) Häufigkeit der Parvovirus B19-Infektio-nen — Seroepidemiologische Untersuchungen. Dtsch Med Wochenschr 112:1526–1531PubMedCrossRefGoogle Scholar
  7. 7.
    Cohen BJ, Buckley MM (1988) The prevalence of antibody to human parvovirus B19 in England and Wales. J Med Microbiol 25:151–153PubMedCrossRefGoogle Scholar
  8. 8.
    Schwarz TF, Gürtler LG, Zoulek G, Deinhardt F, Roggendorf M (1989) Seroprevalence of human parvovirus B19 infection in Sao Tomé and Principe, Malawi and Mascarene Islands. Zbl Bakt 271:231–236Google Scholar
  9. 9.
    Schwarz TF, Roggendorf M, Deinhardt F (1987) Human parvovirus B19 infections in the UK 1984–86. Lancet i :738–739Google Scholar
  10. 10.
    Anderson MJ, Pattison JR (1984) The human Parvovirus: Brief review. Arch Virol 82:137–148PubMedCrossRefGoogle Scholar
  11. 11.
    Werner GH (1958) Erythema infectiosum. Klin Wschr 36:49–55PubMedCrossRefGoogle Scholar
  12. 12.
    Schwarz TF, Jäger G, Schlipköter UA, Wiersbitzky S, Tiller FW, Hottenträger B, Deinhardt F, Roggendorf M (1990) Parvovirus B19 Infektionen in Deutschland 1987–88. Öff Gesundh-Wes 52:53–57Google Scholar
  13. 13.
    Schwarz TF, Roggendorf M, Deinhardt F (1987) Parvovirus B19-Infektionen — Ausbrach in einer medizinisch-technischen Lehranstalt. Dtsch Med Woschenschr 112:1190Google Scholar
  14. 14.
    Center for Disease Control (1989) Risk associated with human parvovirus B19 infection. Morb Mort Weekly Rep 38:81–97Google Scholar
  15. 15.
    Serjeant GH, Mason R, Topley JM, Serjeant BE (1981) Outbreak of aplastic crisis in sickle cell anaemia associated with parvoviras-like agent. Lancet ii :595–597CrossRefGoogle Scholar
  16. 16.
    Kelleher JF, Luban NLC, Mortimer PP, Kamimura T (1983) Human serum parvovirus: A specific cause of aplastic crisis in children with hereditary spherocytosis. J Pediatrics 102:720–722CrossRefGoogle Scholar
  17. 17.
    Schwarz TF, Roggendorf M, Janka-Schaub G (1988) Aplastic crisis caused by parvovirus B19. Eur J Clin Microbiol Infect Dis 7:87–88PubMedCrossRefGoogle Scholar
  18. 18.
    Wiersbitzky S, Schwarz TF, Schröder C, Bruns R, Jäger G, Ladstätter L (1989) Vaskuläre Purpura und andere Gefäß- und Kreislaufalterationen bei Kindern mit akuter Parvovirus B19-Infektion. Kinderärztl Prax 57:193–197PubMedGoogle Scholar
  19. 19.
    Aussedat R, Fesser P, Pourel J (1987) Coxite aigue de l’adolescent, manifestation unique d’une infection par le parvovirus B19. La Presse Med 16:1978Google Scholar
  20. 20.
    Morinet F, Monsuez JJ, Roger R, Perol Y (1987) Parvovirus B19 associated with pseudoappendicitis. Lancet ii :1466CrossRefGoogle Scholar
  21. 21.
    Schwarz TF, Roggendorf M, Suschke H, Deinhardt F (1987) Human parvovirus B19 infection and juvenile chronic polyarthritis. Infection 15:264–265PubMedCrossRefGoogle Scholar
  22. 22.
    Walsh KJ, Armstrong RD, Turner AM (1988) Brachial plexus neuropathy associated with human parvovirus infection. Br Med J 296:896CrossRefGoogle Scholar
  23. 23.
    Kurtzman GJ, Ozawa K, Cohen BJ, Hanson G, Oseas R, Young NS (1987) Chronic bone marrow failure due to persistent B19 parvovirus infection. N Engl J Med 317:287–294PubMedCrossRefGoogle Scholar
  24. 24.
    Kurtzman GJ, Cohen B, Meyers P, Amunullah A, Young NS (1988) Persistent B19 parvovirus infection as a cause of severe chronic anaemia in children with acute lymphocytic leukaemia. Lancet ii :1159–1162CrossRefGoogle Scholar
  25. 25.
    Coulombel L, Morinet F, Mielot F, Tchernia G (1989) Parvovirus infection, leukaemia, and immunodeficiency. Lancet i :101–102CrossRefGoogle Scholar
  26. 26.
    Davidson JE, Gibson B, Gibson A, Evans TJ (1989) Parvovirus infection, leukaemia and immunodeficiency. Lancet i :102Google Scholar
  27. 27.
    Kurtzman G, Frickhofen N, Kimball J, Jenkins DW, Nienhuis AW, Young NS (1989) Pure red-cell aplasia of 10 years’ duration due to persistent parvovirus B19 infection and its cure with immunoglobulin therapy. N Engl J Med 321:519–523PubMedCrossRefGoogle Scholar
  28. 28.
    Anderson MJ, Higgins PG, Davis LR, Willman JS, Jones SE, Kidd JM, Pattison JR, Tyrrell DAJ (1985) Experimental parvoviral infection in humans. J Inf Dis 152:257–265CrossRefGoogle Scholar
  29. 29.
    Schwarz TF, Roggendorf M, Deinhardt F (1988) Human parvovirus B19: ELISA and immunoblot assays. J Virol Methods 20:155–168PubMedCrossRefGoogle Scholar
  30. 30.
    Cohen BJ, Mortimer PP, Pereira MS (1983) Diagnostic assays with monoclonal antibodies for the human serum parvoviras-like virus (SPLV) J Hyg Camb 91:113–130PubMedCrossRefGoogle Scholar
  31. 31.
    Courouce AM, Beaulieu MJ, Boucharcteau F, Lenel ML, Le Maree N (1985) Viraemia with human parvovirus. Lancet i :1218CrossRefGoogle Scholar
  32. 32.
    Kajigaya S, Shimada T, Fujita S, Young NS (1989) A genetically engineered cell line that produces empty capsids of B19 (human) parvovirus. Proc Natl Acad Sci USA 86:7601–7605PubMedCrossRefGoogle Scholar
  33. 33.
    Salimans MMM, Holsappel S, van de Rijke FM, Jiwa NM, Raap AK, Weiland HT (1989) Rapid detection of human parvovirus B19 DNA by dot-hybridization and the polymerase chain reaction. J Virol Methods 23:19–28PubMedCrossRefGoogle Scholar
  34. 34.
    Mortimer PP, Luban NLC, Kelleher JF (1983) Transmission of serum parvo virus-like virus by clotting-factor concentrates. Lancet ii:482–484CrossRefGoogle Scholar
  35. 35.
    Bartolomei Corsi O, Azzi A, Morfini M, Fauci R, Rossi Ferrini P (1988) Human parvovirus infection in haemophiliacs first infused with treated clotting factor concentrates. J Med Virol 25:165–170PubMedCrossRefGoogle Scholar
  36. 36.
    Lyon DJ, Chapman CS, Martin C, Brown KE, Clewley JP, Flower AJE, Mitchell VE (1989) Symptomatic parvovirus B19 infection and heat-treated factor IX concentrate. Lancet i :1085CrossRefGoogle Scholar
  37. 37.
    Johnson B (1984) Parvovirus Proteins: In: Berns KJ (Hrsg.) The parvoviruses. New York London, Plenum Press, 1984, S. 259–295Google Scholar
  38. 38.
    Siegl G: Biology and pathogenicity of autonomous parvoviruses. In: Berns KJ (Hrsg.) The parvoviruses. New York, Plenum Press, 1984, S. 297–362Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1990

Authors and Affiliations

  • T. F. Schwarz
    • 1
  1. 1.MünchenGermany

Personalised recommendations